Radioimmunotherapy with Iodine-131 Tositumomab in Patients with Low-Grade Non-Hodgkin's B-Cell Lymphoma Does Not Induce Loss of Acquired Humoral Immunity against Common Antigens

2001 ◽  
Vol 100 (1) ◽  
pp. 40-48 ◽  
Author(s):  
T. Nordøy ◽  
A. Kolstad ◽  
M.K. Tuck ◽  
I.S. Aaberge ◽  
A. Husebekk ◽  
...  
Keyword(s):  
B Cell ◽  
Humoral Immunity ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Iodine 131 ◽  
Common Antigens

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

1996 ◽  
Vol 14 (7) ◽  
pp. 1974-1981 ◽  
Author(s):  
M S Kaminski ◽  
K R Zasadny ◽  
I R Francis ◽  
M C Fenner ◽  
C W Ross ◽  
...  
Keyword(s):  
Complete Remission ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
High Rate ◽  
Whole Body ◽  
Hematologic Toxicity ◽  
Low Grade ◽  
Tracer Dose ◽  
Iodine 131

PURPOSE The CD20 B-lymphocyte surface antigen expressed by B-cell lymphomas is an attractive target for radioimmunotherapy, treatment using radiolabeled antibodies. We conducted a phase I dose-escalation trial to assess the toxicity, tumor targeting, and efficacy of nonmyeloablative doses of an anti-CD20 monoclonal antibody (anti-B1) labeled with iodine-131 (131I) in 34 patients with B-cell lymphoma who had failed chemotherapy. PATIENTS AND METHODS Patients were first given tracelabeled doses of 131I-labeled anti-B1 (15 to 20 mg, 5 mCi) to assess radiolabeled antibody biodistribution, and then a radioimmunotherapeutic dose (15 to 20 mg) labeled with a quantity of 131I that would deliver a specified centigray dose of whole-body radiation predicted by the tracer dose. Whole-body radiation doses were escalated from 25 to 85 cGy in sequential groups of patients in 10-cGy increments. To evaluate if radiolabeled antibody biodistribution could be optimized, initial patients were given one or two additional tracer doses on successive weeks, each dose preceded by an infusion of 135 mg of unlabeled anti-B1 one week and 685 mg the next. The unlabeled antibody dose resulting in the most optimal tracer biodistribution was also given before the radioimmunotherapeutic dose. Later patients were given a single tracer dose and radioimmunotherapeutic dose preceded by infusion of 685 mg of unlabeled anti-B1. RESULTS Treatment was well tolerated. Hematologic toxicity was dose-limiting, and 75 cGy was established as the maximally tolerated whole-body radiation dose. Twenty-eight patients received radioimmunotherapeutic doses of 34 to 161 mCi, resulting in complete remission in 14 patients and a partial response in eight. All 13 patients with low-grade lymphoma responded, and 10 achieved a complete remission. Six of eight patients with transformed lymphoma responded. Thirteen of 19 patients whose disease was resistant to their last course of chemotherapy and all patients with chemotherapy-sensitive disease responded. The median duration of complete remission exceeds 16.5 months. Six patients remain in complete remission 16 to 31 months after treatment. CONCLUSION Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in patients with B-cell lymphoma refractory to chemotherapy.

Molecular analysis of low grade extranodal marginal zone B-cell lymphoma by alumorph genotyping

2000 ◽  
Vol 118 (4) ◽  
pp. A1385
Author(s):  
Michele De Boni ◽  
Francesco Bertoni ◽  
Roman Mullenbach ◽  
Enrico Roggero ◽  
Angelo Bellumat ◽  
...  
Keyword(s):  
B Cell ◽  
Molecular Analysis ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade

Clinicopathological analysis of splenic red pulp low‐grade B‐cell lymphoma

2020 ◽  
Vol 70 (5) ◽  
pp. 280-286
Author(s):  
Takaharu Suzuki ◽  
Hiroaki Miyoshi ◽  
Joji Shimono ◽  
Keisuke Kawamoto ◽  
Fumiko Arakawa ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Clinicopathological Analysis ◽  
Splenic Red Pulp ◽  
Red Pulp

scholarly journals Extranodal marginal zone non Hodgkin's lymphoma of the lung: A ten-year experience

2011 ◽  
Vol 68 (2) ◽  
pp. 150-154 ◽  
Author(s):  
Violeta Milosevic ◽  
Andrija Bogdanovic ◽  
Snezana Jankovic ◽  
Maja Perunicic-Jovanovic ◽  
Biljana Mihaljevic
Keyword(s):  
B Cell ◽  
Marginal Zone ◽  
Cell Lymphoma ◽  
Performance Status ◽  
Eastern Cooperative Oncology Group ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Chop Regimen ◽  
Female Ratio ◽  
Balt Lymphoma

Background/Aim. Bronchus-associated lymphoid tissue (BALT) lymphoma is a rare subtype of low grade marginal zone B cell lymphoma representing 10% of all MALT lymphomas. The purpose of this study was to analyze the outcome of this group of patients comparing prognostic parameters and therapy modalities. Methods. A total of eight patients with BALT lymphoma had diagnosed between January 1998 - April 2008 at the Institute of Hematology, Clinical Center of Serbia, Belgrade, and they were included in this retrospective analysis. Results. Male/female ratio was 2/6, the median age was 64 years (range 37-67 years). Six patients had nonspecific respiratory symptoms and all of them had B symptoms. The patients were seronegative for HIV, HCV and HBsAg. Three patients had Sjogren's syndrome, rheumatoid arthritis and pulmonary tuberculosis, respectively. Seven patients were diagnosed by transbronchial biopsy and an open lung biopsy was done in one patient. Patohistological findings revealed lymphoma of marginal zone B cell lymphoma: CD20+/CD10-/CD5-/CyclinD1- /CD23-/IgM- with Ki-67+<20% of all cells. According to the Ferraro staging system, five patients had localized disease (CS I-IIE) and three had stage IVE; bulky tumor mass had 3 patients. All patients had Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. Five patients received monochemotherapy with chlorambucil and 3 were treated with CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone). A complete response (CR) was achieved in 5 patients and a partial response (PR) in 3 of them, treated with chlorambucil monotherapy and CHOP regimen. All patients were alive during a median follow-up period of 49 months (range 6- 110 months). Three patients relapsed after monochemotherapy into the other extranodal localization. They were treated with CHOP regimen and remained in stable PR. Conclusion. BALT lymphoma tends to be localised disease at the time of diagnosis, responds well to monochemotherapy with chlorambucil and has a favourable prognosis.

CD20-negative low-grade B cell lymphoma showing immunophenotypic and genotypic features resembling plasma cell myeloma

2013 ◽  
Vol 209 (7) ◽  
pp. 459-462
Author(s):  
Rie Tabata ◽  
Ryoji Yasumizu ◽  
Chiharu Tabata ◽  
Masaru Kojima
Keyword(s):  
B Cell ◽  
Plasma Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Low Grade ◽  
Plasma Cell Myeloma

scholarly journals Analysis of the Response Time to Involved-Field Radiotherapy in Primary Gastrointestinal Low-Grade B-Cell Lymphoma

2020 ◽  
Author(s):  
Kyu Hye Choi ◽  
Han Hee Lee ◽  
Seung-Eun Jung ◽  
Kyung-Sin Park ◽  
Joo-Hyun O ◽  
...  
Keyword(s):  
Response Time ◽  
B Cell ◽  
Cell Lymphoma ◽  
Early Stage ◽  
B Cell Lymphoma ◽  
Delayed Response ◽  
Low Grade ◽  
Depth Of Invasion ◽  
Best Response ◽  
Significant Difference

Abstract Background Early-stage primary gastrointestinal (GI) low-grade B-cell lymphoma shows good therapeutic response to primary radiotherapy. However, there is no clear guideline for the evaluation of response to radiation therapy currently. The aim of this study was to analyze the relationship between the best response time and the clinical course after radiotherapy. Methods Patients who underwent radiotherapy for treatment of primary GI low-grade B-cell lymphoma from September 2007 to December 2018 at Seoul St. Mary's Hospital were included. Early responders were defined by best response within 6 months after radiotherapy, and delayed responders after 6 months. Clinical and pathological factors associated with delayed response and survival analyses were performed to investigate the recurrence and survival during follow-up. Results A total of 43 patients were evaluated and the number of gastric mucosa-associated lymphoid tissue and duodenal follicular lymphoma was 36 and 7, respectively. All of 43 patients showed complete remission to radiotherapy and the best response time after radiotherapy was a median of 3 months. There were 8 delayed responders with a median duration of 8.9 months. Early and delayed responders were characterized by a significant difference in depth of invasion beyond the mucosal layer. Conclusions Delayed responders did not show differences in oncological outcomes compared with early responders. They were allowed to watch and wait for an additional 6 to 12 months without further treatment.

Sign in / Sign up

Export Citation Format

Share Document